Literature DB >> 23962170

Trends in incidence and predictions of cutaneous melanoma across Europe up to 2015.

M Arnold1, C Holterhues, L M Hollestein, J W W Coebergh, T Nijsten, E Pukkala, B Holleczek, L Tryggvadóttir, H Comber, M J Bento, Ch S Diba, R Micallef, M Primic-Žakelj, M I Izarzugaza, J Perucha, R Marcos-Gragera, J Galceran, E Ardanaz, R Schaffar, A Pring, E de Vries.   

Abstract

BACKGROUND: Melanoma is a significant health problem in Caucasian populations. The most recently available data from cancer registries often have a delay of several months up to a few years and they are generally not easily accessible.
OBJECTIVES: To assess recent age- and sex-specific trends in melanoma incidence and make predictions for 2010 and 2015.
METHODS: A retrospective registry-based analysis was performed with data from 29 European cancer registries. Most of them had data available from 1990 up to 2006/7. World-standardized incidence rates (WSR) and the estimated annual percentage change (EAPC) were computed. Predictions were based on linear projection models.
RESULTS: Overall the incidence of melanoma is rapidly rising and will continue to do so. The incidence among women in Europe was generally higher than in men. The highest incidence rates were seen for Northern and north-western countries like the UK, Ireland and the Netherlands. The lowest incidence rates were observed in Portugal and Spain. The incidence overall remained stable in Norway, where, amongst young (25-49 years) Norwegian males rates significantly decreased (EAPC -2.8, 95% CI -3.6; -2.0). Despite a low melanoma incidence among persons above the age of 70, this age group experienced the greatest increase in risk during the study period.
CONCLUSIONS: Incidence rates of melanoma are expected to continue rising. These trends are worrying in terms of disease burden, particularly in eastern European countries.
© 2013 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Year:  2013        PMID: 23962170     DOI: 10.1111/jdv.12236

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  48 in total

1.  Are General Physicians Prepared for Struggling Skin Cancer?-Cross-Sectional Study.

Authors:  Ana Filipa Duarte; Altamiro da Costa-Pereira; Veronique Del-Marmol; Osvaldo Correia
Journal:  J Cancer Educ       Date:  2018-04       Impact factor: 2.037

2.  Safety of vemurafenib in patients with BRAF V600 mutated metastatic melanoma: the Spanish experience.

Authors:  A M Arance; A Berrocal; J A Lopez-Martin; L de la Cruz-Merino; V Soriano; S Martín Algarra; L Alonso; P Cerezuela; B La Orden; E Espinosa
Journal:  Clin Transl Oncol       Date:  2016-03-17       Impact factor: 3.405

3.  In vivo profiling reveals immunomodulatory effects of sorafenib and dacarbazine on melanoma.

Authors:  Mirjana Urosevic-Maiwald; Marjam J Barysch; Phil F Cheng; Maria B Karpova; Hans Steinert; Michal J Okoniewski; Reinhard Dummer
Journal:  Oncoimmunology       Date:  2015-01-07       Impact factor: 8.110

4.  Patterns of increased incidence and survival of cutaneous melanoma in Girona (Spain) 1994-2013: a population-based study.

Authors:  J Rubió-Casadevall; M Puig-Vives; M Puigdemont; L Vilardell; A Carbó-Bagué; R Marcos-Gragera; N Vilar-Coromina
Journal:  Clin Transl Oncol       Date:  2018-06-05       Impact factor: 3.405

5.  Risk of skin cancer among patients with myotonic dystrophy type 1 based on primary care physician data from the U.K. Clinical Practice Research Datalink.

Authors:  Youjin Wang; Ruth M Pfeiffer; Rotana Alsaggaf; Wilhelmine Meeraus; Julia C Gage; Lesley A Anderson; Renée C Bremer; Nikoletta Nikolenko; Hanns Lochmuller; Mark H Greene; Shahinaz M Gadalla
Journal:  Int J Cancer       Date:  2017-11-20       Impact factor: 7.396

6.  Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma.

Authors:  Jacqueline Dinnes; Lavinia Ferrante di Ruffano; Yemisi Takwoingi; Seau Tak Cheung; Paul Nathan; Rubeta N Matin; Naomi Chuchu; Sue Ann Chan; Alana Durack; Susan E Bayliss; Abha Gulati; Lopa Patel; Clare Davenport; Kathie Godfrey; Manil Subesinghe; Zoe Traill; Jonathan J Deeks; Hywel C Williams
Journal:  Cochrane Database Syst Rev       Date:  2019-07-01

7.  Reflectance confocal microscopy for diagnosing cutaneous melanoma in adults.

Authors:  Jacqueline Dinnes; Jonathan J Deeks; Daniel Saleh; Naomi Chuchu; Susan E Bayliss; Lopa Patel; Clare Davenport; Yemisi Takwoingi; Kathie Godfrey; Rubeta N Matin; Rakesh Patalay; Hywel C Williams
Journal:  Cochrane Database Syst Rev       Date:  2018-12-04

8.  Cytoplasmic CK1ε Protein Expression Is Correlated With Distant Metastasis and Survival in Patients With Melanoma.

Authors:  Jeng-Wei Lu; Shu-Hui Lin; Chung-Min Yeh; Kun-Tu Yeh; Lan-Ru Huang; Chia-Yu Chen; Yueh-Min Lin
Journal:  In Vivo       Date:  2020 Sep-Oct       Impact factor: 2.155

9.  Outcomes and Risk Factors in Patients with Multiple Primary Melanomas.

Authors:  Adi Nosrati; Wesley Y Yu; Joseph McGuire; Ann Griffin; Juliana Rocha de Souza; Rasnik Singh; Eleni Linos; Mary Margaret Chren; Barbara Grimes; Nicholas P Jewell; Maria L Wei
Journal:  J Invest Dermatol       Date:  2018-07-19       Impact factor: 7.590

10.  Variations in supportive care needs of patients after diagnosis of localised cutaneous melanoma: a 2-year follow-up study.

Authors:  Vanessa L Beesley; B Mark Smithers; Peter O'Rourke; Monika Janda; Kiarash Khosrotehrani; Adèle C Green
Journal:  Support Care Cancer       Date:  2016-08-25       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.